Asia-Pacific Dementia Treatment Market Report 2024

Asia-Pacific Dementia Treatment Market Report 2023 Market Size Split by Type (Alzheimer’s Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia, Parkinson Disease Dementia, Others), Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonist, MAO Inhibitors, Combination Drug, Others), Route of Administration (Oral, Transdermal Patch, Injectable), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Asia-Pacific Dementia Treatment Market Report Description

Read a Detailed Qualitative analysis of the above report by requesting the free sample pages from Request for your Free Sample PDF/Online Access.

Competitive Landscape: Dementia Treatment Market

To meet the increasing demands of consumers the industry players are now investing and giving more attention to their research and development of Dementia Treatment so that they sustain and survive in the competition. ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.
 

Top Companies Market Share in Asia-Pacific Dementia Treatment Industry: (In no particular order of Rank)

• Pfizer Inc.
• Brain Scope
• Lilly
• Biogen
• Viatris Inc.
• Johnson & Johnson
• Abbvie Inc
• Sun Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Otsuka Pharmaceutical Co. Ltd
• Cipla Inc.
• H. Lundbeck A/S
• Apotex Inc.
• F. Hoffmann- La Roche AG
• Teva Pharmaceutical Industries
• Merz Pharma GmbH & Co. KGaA
• Mylan N.V
• Dr. Reddy Laboratories Ltd
• Zydus Cadila
• Allergan plc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Asia-Pacific Dementia Treatment Market Analysis

The Alzheimer's dementia type segment accounts for the largest market share and is expected to rise over the period. According to the Alzheimer's Association 2021 report, the US Food and Drug Administration (FDA) has approved five medications for Alzheimer's treatment: rivastigmine, galantamine, donepezil, memantine, and memantine coupled with donepezil. The study also found that the vast majority of patients who develop Alzheimer's disease are 65 years or older. This is known as late-onset Alzheimer's. Furthermore, in the United States, Alzheimer's dementia affects about 5.3% of persons aged 65 to 74, 13.8% of those aged 75 to 84, and 34.6% of people aged 85 and up. In addition, an estimated 6.2 million Americans aged 65 and older will be living with Alzheimer's dementia in 2021, with a predicted increase to 13.5 million by 2050.
(Source-https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048103)

Vascular dementia is the market's fastest-growing sector, defined as cognitive impairment caused by impaired blood flow to the brain. This type of dementia is commonly caused by a stroke or other vascular problems. Pharmaceutical therapies in this section are intended to target the underlying vascular causes and prevent additional cognitive loss. Treatment plans frequently include risk factor management, such as hypertension and diabetes.

Note: The above Chart is for representative purposes and does not depict actual sales & statistics. You can request a free sample or purchase the full report access today!

In 2023, cholinesterase inhibitors dominated the market, accounting for XX% of the total. High prescription rates for donepezil, rivastigmine, and galantamine, as well as improved results, are significant drivers of market expansion. Furthermore, the increasing use of transdermal cholinesterase inhibitors, as well as their superior safety and efficacy, are driving market expansion. For instance, Corium, LLC reported data in September 2023 indicating that Adlarity (donepezil transdermal system) demonstrated positive outcomes in terms of skin tolerability and adherence in a placebo-controlled experiment.
(Source-https://www.dermatologytimes.com/view/donepezil-patch-shows-favorable-results-on-skin-irritation-trial)
However, the combination pharmaceuticals market is expected to have the fastest compound annual growth rate (CAGR) between 2024 and 2033. This expansion is being driven by the increasing use of combination medication, which has proven to be more effective than monotherapy. Furthermore, significant players are releasing novel combination medications to the marketplace. For instance, in April 2022, NovaMedica developed and registered a combination of donepezil and memantine molecules under the brand name Mioreol in Russia and Europe. The increasing global approval of combination treatments containing cholinesterase inhibitors and NMDA receptor antagonists is propelling expansion in this segment.
(Source-https://novamedica.com/media/our_news/p/12767-novamedica-launches-own-innovative-drug-for-the-treatment-of-alzheimers-disease)

Note: The above Chart is for representative purposes and does not depict actual sales & statistics. You can request a free sample or purchase the full report access today!

Asia-Pacific Dementia Treatment Route of Administration Segment Analysis

The oral method of administration led the market in 2023 with a share of XX% and is expected to maintain its dominance in the coming years. The high market penetration of oral pharmaceuticals such as memantine, donepezil, rivastigmine, galantamine, and others, the large number of pharmaceutical companies supplying these oral drugs, and the increasing approval of oral drugs are the primary reasons driving the segment's expansion. For instance, in May 2023, the US FDA granted additional approval for Rexulti (brexpiprazole) oral tablets to treat dementia-related agitation.
(Source-https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease#:~:text=Today%2C%20the%20U.S.%20Food%20and,treatment%20option%20for%20this%20indication.)

The injectable pharmaceuticals segment is expected to expand at the fastest compound annual growth rate (CAGR) from 2024 to 2033. This expansion is being driven by increased research and development initiatives targeted at producing innovative biological therapies, as well as the approval of injectable medications that have demonstrated enhanced efficacy in treating dementia. For Instance, in July 2021, Biogen and Eisai Co., Ltd. got FDA approval for Aduhelm injectable to treat dementia caused by Alzheimer's disease.
(Source-https://www.eisai.com/news/2021/news202141.html)

• Oral
• Transdermal Patch
• Injectable

Asia-Pacific Dementia Treatment Distribution Channel Segment Analysis

In 2023, hospital pharmacies dominated the market, accounting for XX% of the total. The older population's increasing hospitalization rate due to dementia is driving the segment's rise. According to the Alzheimer's Association Report 2023, there were 518 hospitalizations per 1,000 Medicare beneficiaries aged 65 and older with Alzheimer's or other types of dementia, compared to just 234 hospitalizations per 1,000 Medicare beneficiaries who did not have these disorders.
(Source-https://www.alzsd.org/wp-content/uploads/2023/03/Michelle-Reuwers-Summary-of-the-2022-Alzheimers-Disease-Facts-and-Figures-Report.pdf)

On the other side, the internet category is expected to develop at the fastest compound annual growth rate (CAGR) between 2024 and 2033. This expansion is being driven by factors such as an expanding internet and smartphone user base, the convenience of obtaining drugs through e-commerce platforms, and the increased availability of online pharmacies around the globe. Furthermore, the increased use of telemedicine to manage mental health is projected to fuel growth in this segment in the coming years.

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Asia-Pacific Dementia Treatment Country Analysis

In this section we have included market revenue, share, type, application and other segment analysis for each country level. Our team identifies and analyses potential risks associated with operating in each country, including rules and regulations, geopolitical risks, and other market-specific challenges. We estimate historical data and forecast future trends to understand the market's current situation in each country. This analysis helps key players to build strategies to strengthen their foothold in Asia-Pacific Dementia Treatment market.

• China
• Japan
• Korea
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest of APAC

The Current Published report Editon on the website includes the following list of countries analysis whereas in case you looking to access any other country or states level data under Asia Pacific then please revert us to access the exclusive Asia-Pacific Dementia Treatment industry report Edition.

The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!

The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of this market.

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Bio :

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the medical...Read More

Author's Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Asia-Pacific Dementia Treatment Market is witnessing significant growth in the near future.

In 2023, the Alzheimer’s Dementia segment accounted for noticeable share of Asia-Pacific Dementia Treatment Market and is projected to experience significant growth in the near future.

The Cholinesterase Inhibitors segment is expected to expand at the significant CAGR retaining position throughout the forecast period.

Some of the key companies Pfizer Inc. , Lilly and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the market.

Frequently Asked Questions

What is Asia-Pacific Dementia Treatment market size/share and growth rate?

Asia-Pacific Dementia Treatmentmarket size and its growth rate has been provided in the report. The historical period included in the report is from 2019 to 2023, whereas, the report provides forecast data for the years 2023 to 2030. This will help you to in terms of market share, regional market share, country level market share to understand how the market has been performing in the past and how it is going to perform in the following years. Correspondingly, historical and forecast analysis comprises sales and revenue data of the Asia-Pacific Dementia Treatmentmarket. Market size for UK, Europe, North America, Asia Pacific, Middle East & Africa is also included in the report.

What are the major factors affecting the Asia-Pacific Dementia Treatment market?

The major factors affecting the Asia-Pacific Dementia Treatment market in a positive, as well as negative perspective, have been provided with detailed analysis in the report. This segment has encompassed drivers, opportunities, and challenges faced by the industry. This will help you to understand the major factors impacting Asia-Pacific Dementia Treatment market trends and develop your business strategy accordingly.

Who are the top manufacturers of Asia-Pacific Dementia Treatment? List of Asia-Pacific Dementia Treatment Companies and there market trend or market share?

Major manufacturers or list of Asia-Pacific Dementia Treatment manufacturers 2023 involved in the market have been profiled in the report along with their business strategies, recent developments, SWOT analysis, business overview, and market Trend from the year 2018-2022. Asia-Pacific Dementia Treatment Companies such as Pfizer Inc., Brain Scope, Lilly, Biogen, Viatris Inc., Johnson & Johnson, Abbvie Inc, Sun Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd, Cipla Inc., H. Lundbeck A/S, Apotex Inc., F. Hoffmann- La Roche AG, Teva Pharmaceutical Industries, Merz Pharma GmbH & Co. KGaA, Mylan N.V, Dr. Reddy Laboratories Ltd, Zydus Cadila, Allergan plc. are part of the final deliverable document along with the same we can provide data for 2nd, 3rd, start-up level companies data and strategies as well. This will help you to understand the competitive analysis of the market and how other players are performing in the market. This detailed competitive analysis will help you to strategize your business accordingly and will keep you one step ahead. A quantitative and qualitative analysis of the main players in the Asia-Pacific Dementia Treatment market is introduced, from the perspective of sales, revenue and price.

Which segments are covered under Asia-Pacific Dementia Treatment market segments analysis?

Under Asia-Pacific Dementia Treatment market segments analysis Type, Drug Class, Route of Administration. It provides detailed insights on each type and application. Further, it provides which sub-segment is dominating the Asia-Pacific Dementia Treatment market along with its reason. Additionally, the Asia-Pacific Dementia Treatment market report will help you to analyze which sub-segment is fastest-growing during the forecast period.

What has been the impact of COVID-19 on the Asia-Pacific Dementia Treatment market?

After the analysis of the complete market, the report has provided how the COVID-19 pandemic has affected the market. All the parameters have covered the overall impact of COVID -19 on the market value, market trend & growth of the market, and how the major players in the particular market are adopting these changes. This will help you to understand the overall optimistic, pessimistic, and neutral effects of the coronavirus pandemic on the Asia-Pacific Dementia Treatment market.

How the Asia-Pacific Dementia Treatment market performed till 2023 and how will it perform in the following years?

The Asia-Pacific Dementia Treatment market has been analyzed thoroughly and has estimated the parameters which have affected the market in the historical period as well as how the market is going to perform in the following years. This will provide a complete market scenario and help you to strategize your next move accordingly to the Asia-Pacific Dementia Treatment market Share.

Which region is expected to hold the highest market share in the Asia-Pacific Dementia Treatment market?

The report gives an exhaustive investigation of the Asia-Pacific Dementia Treatment market at country & regional levels, and provides an analysis of the industry trends in each of the regions, from sales, revenue, and consumption. It will help you to understand which region is dominating the market and is expected to grow significantly in the following years. The regional analysis will help you in strategizing the expansion of business.

What are the parameters used to analyze market position?

Asia-Pacific Dementia Treatmentmarket report has provided PESTEL and Porter analysis to provide insightful information regarding the market scenario. It also provides market attractiveness analysis with an acknowledgment of various factors within the market, including growth rate and market size, as well as outside factors such as access to raw materials, competition, and industry capacity.

How to order Full Report or Sample pages of the Asia-Pacific Dementia Treatment market?

The sample report for the Asia-Pacific Dementia Treatment Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.